Medical news
of the North Caucasus
Scientific journal
Mass media registration certificate dated December 7, 2006.
Series ПИ #ФС 77-26521.
Federal service for surveillance over non-violation of the legislation in the sphere of mass communications and protection of cultural heritage.
ISSN 2073-8137

Site search

Correspondence address
310 Mira Street, Stavropol, Russia, 355017

+7 8652 352524; +7 8652 353229.

+7 8652 352524.


Approaches to predicting the efficacy and safety of amlodipine in patients with arterial hypertension of I–II degree based on pharmacogenetic studies

[Original research]
Dmitry Sychev; Evgeniya Shih; Tatiana Evgenyevna Morozova; Artur Damirovich Ismagilov; Evgeniya Shih; Karin Badavievich Mirzaev; Sarvinoz Sharafidinovna Atakulova;

At the study conducted of increase the efficacy and safety of therapy in patients with arterial hypertension (AH) of I–II degree by personalizing the choice of amlodipine dosage regimen based on genotyping by ABCВ1, CYP3A5, and phenotyping by CYP3A4. Clinical and pharmacogenetic study of amlodipine was conducted with 100 patients with arterial hypertension I–II degree between the ages of 42 to 58, (m – 45 %, f – 55 %). The «SNP-Screen» set («Sintol», Russia) was used to determine the polymorphism of the CYP3A5 gene. The metabolic activity of the CYP3A4 isoenzyme was determined by high-performance liquid chromatography (HPLC). The metabolic activity of CYP3A4 was calculated from the 6-beta-hydroxycortisol/cortisol ratio in the morning urine. Our study showed associations between the CYP3A5 gene from the polymorphic marker A6986G and the safety profile of amlodipine, and the lack of significant influence of the course of amlodipine on CYP3A4 activity. In the AG genotype of the CYP3A5 gene, higher antihypertensive efficacy is associated with a higher risk of developing ADR, whereas in the GG genotype – lower efficacy and less risk of developing ADR. The activity of CYP3A4 does not change with the background use of amlodipine (p=0.06). The obtained pharmacogenetic data make it possible to propose an algorithm for personalized choice of the dosage regimen of amlodipine for patients with an AH I–II degree.


1. Federal Guideline to Medication administration. Publication № XIIII. 2012:157-168.
2. Resolution of the Government of the Russian Federation № 2343-r of 29 December. 2005.
3. The ALLHAT Officers and coordinators for the ALLHAT collaborative research group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone. The Antihypertensive and Lipid-Lowering Treatment to prevent Heart Attack Trial (ALLHAT). JAMA. 2000; 283: 1967–75. https://doi:10.1001/jama.288.23.2981
4. Julius S., Kjeldsen S. E., Weber M. [et al.] Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine. The VALUE randomized trial. Lancet. 2004;363(9426):2022-31. https://doi.org/10.1007/s12325-008-0042-x
5. Bakris G. L., Sarafidis P. A., Weir M. R. [et al.] Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a Randomized controlled trial. Lancet. 2010;375(9721):1173-81. https://doi.org/10.1016/S0140-6736(09)62100-0
6. Diagnosis and treatment of arterial hypertension. Clinical recommendations. Kardiologicheskiy Vestnik. 2015;10(1):30-31.
7. Chazova I. Ye., Zhernakova Yu. V., Oshchepkova Ye. V. [et al.] Prevalence of risk factors for cardiovascular diseases in the Russian population of patients with arterial hypertension. Kardiologiia. 2014;10:4-12.
8. Sychev D., Shikh N., Morozova T., Grishina E., Ryzhikova K. [et al.] Effects of ABCB1 rs1045642 polymorphisms on the efficacy and safety of amlodipine therapy in Caucasian patients with stage I–II hypertension. Pharmacogenomics Pers. Med. 2018;11:157-165. https://doi.org/10.2147/PGPM.S158401
9. Guo C., Pei Q. I., Tan H. [et al.] Effects of genetic factors on the pharmacokinetics and pharmacodynamics of amlodipine in primary hypertensive patients. Biomed. Rep. 2015;3(2):195-200. https://doi.org/10.3892/br.2014.395
10. Huang Y., Wen G., Lu Y. [et al.] CYP3A4*1G and CYP3A5*3 genetic polymorphisms alter the antihypertensive efficacy of amlodipine in patients with hypertension following renal transplantation. Int. J. Clin. Pharmacol. Ther. 2017;55(2):109-111. http://doi.org/10.5414/CP202559

Keywords: pharmacogenetics, personalized medicine, gene polymorphisms, arterial hypertension, amlodipine

Stavropol State Medical Academy
Pyatigorsk State Research Institute of Balneotherapeutics
Pyatigorsk State Pharmaceutical Academy